Abstracts tagged "Autoinflammatory diseases"

Abstract Number: 0559 • ACR Convergence 2020
Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Autoimmune/autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated in a Single Hospital from Colombia
Consuelo Romero-Sanchez¹, Omar-Javier Calixto², Veronica Romero², Diana Rincon Riano³, Julio Amador², Luis Castro², Pedro Lopez-Mojica⁴, Daniela Marin², Diana Àcero⁵, Monica Acevedo⁵, Wilson Bautista-Molano⁶ and Juan Manuel Bello-Gualtero⁷, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Hospital Militar Central, Universidad Militar Nueva Granada, Bogota, Colombia, ³Universidad Militar Nueva Granada, Bogota, Colombia, ⁴Hospital Militar Central, Universidad Militar Nueva Granada, BOGOTA, Distrito Capital de Bogota, Colombia, ⁵Hospital Militar Central, Bogota, Colombia, ⁶University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia, ⁷Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia
Background/Purpose: Autoimmune systemic rheumatic disease (SARD) diagnostic approach is complex and recently there are some diagnostic tools to rule-out autoimmune disease diagnoses. ANAS/DFS70 antibodies have…
Abstract Number: 1412 • ACR Convergence 2020
A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome
Ruth Napier¹, Ellen Lee¹, Emily Vance¹, Sydney Lashley², Luke Uebelhoer³, Christina Lancioni³, Richard Vehe⁴, Bryce Binstadt⁴, Rachel Caspi⁵ and Holly Rosenzweig¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Oregon Health & Science University, Portland, ⁴University of Minnesota, Minneapolis, MN, ⁵NIH, Bethesda, MD
Background/Purpose: Mutations in nucleotide-binding oligomerization domain-containing protein 2 (NOD2) cause Blau syndrome, an inflammatory disorder characterized by uveitis, dermatitis, and polyarthritis. The antimicrobial functions of NOD2 are…
Abstract Number: 0082 • ACR Convergence 2020
Diffuse Sclerosing Osteomyelitis of the Jaw: An Underdiagnosed Disease in Maxillofacial Surgery Department
Pauline Preuss¹, Hélios Bertin¹, Pierre Corre¹ and Benoit Le Goff², ¹Nantes University Hospital, Nantes, France, ²Nantes University Hospital, Nantes, Pays de la Loire, France
Background/Purpose: Diffuse sclerosing osteomyelitis of the jaw is a rare and under-recognized disease. Many authors include this diagnosis in the spectrum of aseptic osteitis sometimes…
Abstract Number: 0874 • ACR Convergence 2020
A Multi-Center, Randomized, Double-blind, Placebo-controlled Dose-ranging Study Evaluating Efficacy and Safety of SHR-1314 in Subjects with Moderate-to-Severe Plaque Psoriasis
Chunlei Zhang¹, Kexiang Yan², Qingchun Diao³, Qing Guo⁴, Hongzhong Jin⁵, Sen Yang⁶, Xiang Chen⁷, Tiechi Lei⁸, Jianhua Wu⁹, Hong Yu¹⁰, Min Zheng¹¹, Xinghua Gao¹², Robert Sinclair¹³, Delilah Alonso¹⁴, Yi Zhu¹⁵, Qian Xu¹⁵ and Jinhua Xu², ¹Department of Dermatology, Peking University Third Hospital, Beijing, China (People's Republic), ²Huashan Hospital Affiliated to Fudan University, Shanghai, China (People's Republic), ³Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China (People's Republic), ⁴Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic), ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ⁶The First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ⁷Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, China (People's Republic), ⁹Changhai Hospital of Shanghai, Shanghai, China (People's Republic), ¹⁰Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ¹¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ¹²The 1st Hospital of China Medical University, Shenyang, China (People's Republic), ¹³Sinclair Dermatology, East Melbourne, Australia, ¹⁴Revival Research, Doral, ¹⁵Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic)
Background/Purpose: SHR-1314 is a humanized monoclonal immunoglobulin (IgG1/κ isotype) targeting human interleukin-17A (IL-17A). Preliminary data from phase I study has shown that single dose of…
Abstract Number: 1413 • ACR Convergence 2020
An Imbalance Between Regulatory and Inflammatory T Cell Subsets Distinguishes Systemic Autoimmune Rheumatic Disease Patients from Asymptomatic ANA+ Individuals
Emma Vanlieshout¹, Rashi Gupta¹, Dennisse Bonilla², Michael Kim³, Sindhu Johnson², Earl D. Silverman⁴, Linda Hiraki⁵, Zareen Ahmad⁶, Zahi Touma⁷, Arthur Bookman² and Joan Wither², ¹Krembil Research Institute, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Krembil Research Insitute, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: The anti-nuclear antibody (ANA)-associated systemic autoimmune rheumatic diseases (SARDs) are characterized by a prolonged preclinical phase in which ANAs are produced in the absence…
Abstract Number: 803 • 2019 ACR/ARP Annual Meeting
Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
Kenan Barut ¹, Amra Adrovic ², Sezgin Sahin ³, Mehmet Yıldız ², Oya Koker ², Gamze Yalcin ², Omer Faruk Beser ⁴, Bekir Kocazeybek ⁵, Pelin Yuksel ⁵ and Ozgur Kasapcopur⁶, ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ²Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ⁴Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Istanbul, Turkey, ⁵Department of Microbiology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ⁶Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].